Barry Hyman
Barry Hyman
bonds gone housing improve influenced market rates trends
The market did improve with the housing data. Market trends day to day are really influenced by how the bonds have been trading. When the rates have gone up, equities have suffering, when rates have gone down, the market has been optimistic.
bond cusp helped market outlook resistance retail rewarded sales stocks strong taking tame technology
The tame retail sales outlook helped the bond market. The market rewarded that with a very strong day. Financials and technology stocks righted themselves. We're on the cusp of taking out some important resistance levels.
activity assume bond economic feeling further gives higher interest market people rates signs whether worry
There's worry about higher interest rates. The bond market has been very weak, and we can assume the higher interest rates are signs of a rebounding economy. This gives people a feeling of comfort, but we also worry about how rates are going to go and whether it will crimp economic activity further down the road.
bond concern continue defensive equity fed market number numbers pressure raising seeing shows store stressed
Now we're going to see more pressure on the bond market and an already stressed equity market. There's a lot of concern and we're seeing some defensive investing. This number shows that the Fed will continue raising rates. Numbers like this show that we're in store for two more hikes.
bond feeling fine headed heading interest key looks market rates starting street struggling technical wall
The 10-year bond looks like it's headed higher, so I think the feeling is starting to pervade Wall Street that economy's fine and interest rates are heading higher. But the market has (also) been choppy and struggling with some key technical levels.
maintain market percentage point quarter whether wire
I think we're going to go down to the wire whether or not it's a half-percentage point (increase). If you want to maintain market stability, a quarter percentage point could keep the market at bay.
clears discount happened market number tomorrow
A worse-than-expected number tomorrow will discount what happened this week. If we get an inflationary number, the market will go down, but I think it all clears up by mid-June.
divert hard money phenomenal quickly stocks
I think it's just more of the same. The Nasdaq is quickly approaching 5,000 and it's hard to divert money back to traditional stocks when the opportunities are so phenomenal in the new world economy.
accumulate aware easier fed great investor late looking next problems rally small start stock summer tech technology three trading vigorous weak worried
I think it's too late to be worried about where your tech stock is going to go from here. There are some opportunities out there and we are aware of the short-term problems in the marketplace with the Fed being aggressive. So, we're not looking for a very vigorous rally over the next one to three months. There will be trading rallies. But the investor, the small investor, the intermediate-to-long-term investor should use the summer time, which is seasonally weak for technology stocks, to start to accumulate an easier way into some of these great companies,
generally intel run seeing stock
Intel was generally positive, but I think the stock had run up into the meeting, so that's why you're not seeing much reaction.
increased market volatility
At the same time, there is this increased market volatility that exaggerates these swings.
accounting worries
There's still some overhang from the accounting worries out there.
dramatic earnings fed late market meeting news next until
There really isn't any dramatic news to come out post-Fed ? we're going to get into that earnings void, the next meeting for the Fed isn't until late June, so I think the story is how well the pullback in this market will be contained.
benefit both companies deals dollars eventually good help helps high marketing merger sector strike terms toward
I think, ... that Pfizer is going to benefit from their merger with Warner-Lambert. I think that makes a very good deal. But most pharmaceutical companies do eventually strike deals with biotech companies in terms of marketing their product. And the genomic companies don't have a lot of cash. They have a lot of high valuations, but they don't have a lot of dollars to spend. So, they usually look toward the pharmaceutical sector to help them out, which usually helps both sectors.